Fresh safety, tolerability data snapshot from early-stage study of Wave's DMD drug spooks investors
Wave Life Sciences irked investors with the latest snapshot of safety data on its experimental Duchenne muscular dystrophy (DMD) drug on Tuesday, causing Wall Street to question whether the results from the early-stage study foreshadowed trouble ahead.
The experimental drug, suvodirsen, is being tested in the same DMD population that Sarepta’s $SRPT pioneering Exondys 51 is approved to treat — boys who are amenable to exon 51 skipping. In the Phase I study, 36 patients received a dose of 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg, 7 mg/kg or 10 mg/kg of suvodirsen (n=26) or placebo (n=10) in five ascending dose cohorts and were followed for 85 days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.